Anavex’s Once-Daily Oral Dementia Treatment Shows Promise in Phase IIb/III Trial
Anavex Life Sciences Corp. has unveiled promising results from its landmark Phase IIb/III clinical trial of blarcamesine (ANAVEX®2-73), a potential once daily oral dementia treatment for early Alzheimer’s disease. The findings, presented at the 2024 Alzheimer’s Association International Conference (AAIC), demonstrate significant slowing of clinical decline in patients with early Alzheimer’s disease. The study, conducted…